Pfizer’s RSV Vaccine For Pregnant Women Not Linked To Greater Risk Of Pre-Term Or Early Births, Study Suggests

Reuters (7/8, Santhosh) reports, “Pfizer’s respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.” Researchers conducted a “retrospective study in women who were 24 to 36 weeks into pregnancy, and found no significant statistical difference between the vaccinated women’s pre-term birth rate of 5.9% compared with unvaccinated women’s 6.7%.” The findings were published in JAMA Network Open.